Pneumoconiosis (PAP) is a rare pulmonary disease, with a large amount of insoluble phosphates deposited in small trachea and in the lungs, leading to air-replacement and aerobic dysfunctions, causing respiratory difficulties and respiratory failure when severe. The following is a detailed account of the treatment of pneumoconiosis:
I. Diagnosis
1. Clinical performance
Respiratory difficulties are usually experienced by patients, which are the most common symptoms of pneumoblico-sedimentation and are often aggravated. In addition, patients may be associated with coughing, coughing (mostly white or yellow), indigence, loss of appetite and weight loss. Some patients may not have visible symptoms or show signs of fever, damp pulmonary pronunciation, etc. following the infection.
2. Visual inspection
Chest X-rays: may indicate a contagious disease in the lung, but not very specific.
High resolution CT (HRCT): Pneumophorism shows on the HRCT the “roadstones” of map distribution, which is typical of the image of pneumophorism.
3. Pulmonary bubble sapling
Pneumoporosis tests are a key step in the diagnosis of pneumoconiosis. Pneumoculars are rinsed through bronchoscopy, and irrigation fluids are collected and tested.
Appearances: Reaping fluids may be obscurant, with visible sediments visible after static or centrifugal.
Spectroscopy: The sediments in the irrigated fluids are spectroscopyed, and the mesoplasmic fine granulate-like proteins are visible, sometimes in needle fractures.
Electroscope examination: Under the lens see a small tectonic structure of an onion-like cortex, a characterizational pathology of pulmonary bubble protein deposition.
Lung biopsy
While pulmonary pneumoconiosis tests can identify most pneumoconiosis patients, some of them may need a pulmonary tissue biopsy to clearly diagnose them. Pulmonary tissue biopsy can show that the pulmonary bubble structure is good, but the pulmonary bubble is filled with fine particles or lactose proteins, which are typical pathologies of pneumatic protein deposition.
5. Other inspections
Pulmonary function examination: may indicate a decrease in restricted aerodynamic disorders and dispersive functions.
Arterial haemorrhagic analysis: low oxygen haemorrhage and carbon dioxide retention are possible.
aPP seroprevalence anti-GM-CSF antibodies: for patients with ad hoc pneumoblico-sedimentation, the seroprevalence anti-pneumococtal-corpolytic irritation factor (GM-CSF) may increase significantly.
6. Diagnostic criteria
Clinical performance consistent with pneumoconiosis:
Imagery tests show typical “roadstones” to grind glass.
Pneumocular slurry tests showed the deposition of proteins.
Pulmonary tissue biopsy shows pneumoblicoprotein filling.
There are currently no uniform diagnostic criteria, and many of the above criteria are met, in particular the results of visual examinations, pulmonary pneumatic pneumoconiosis and pulmonary tissue biopsy, which can be detected.
Treatment
General treatment
Good moods: patients need to maintain a good mindset and cooperate actively with the treatment to help them recover.
Improvement of living habits: cessation of smoking, prevention of alcohol, avoidance of inhalation of harmful substances, maintenance of good living habits, help to increase their resilience.
Nutritional support: Improved nutrition and a balanced diet contribute to increased body immunity.
2. Drug treatment
Particle Cyclastic Cyclastic Irritation Factor (GM-CSF): Activation mechanism: GM-CSF stimulates the growth and fragmentation of pulmonary bubble Cyclops and enhances their ability to swallow and remove proteins from their pneumatic cavity.
Littoce: A mechanism for action: Littocetone is a single cloned antibody that combines with the antigen specificity of the CD20 on the gonorrhoea cell, inhibits the generation of its own immune antibodies, and may have a therapeutic effect on ad hoc pulmonary bubble protein deposition. Treatment: The current treatment is not accurate, but studies have shown that it reduces the level of anti-GM-CSF in patients.
Attention: When used, changes in patient ‘ s condition need to be closely monitored and treatment programmes adjusted in a timely manner.
Other drugs: sugar cortex hormones, such as capone, acetic acid and so on, can inhibit pneumoconiosis and promote its absorption. Attention needs to be paid to possible side effects such as osteoporosis and increased blood sugar. Immunosuppressants, such as cyclophosphate, sulfur, can inhibit the release of inflammatory factors and reduce the response to pneumonia. However, long-term use may increase the risk of infection. Anti-fibrosis drugs, such as thiphonone, Nidanib, can reduce pneumonia and promote inter-pulmonary fibrosis. However, attention needs to be paid to the possible adverse effects of gastrointestinal reactions, rashes, etc.
3. Full pulmonary irrigation
Large-volume full-pulmonary hysteria is one of the most effective treatments for pneumoconiosis and can significantly improve the clinical symptoms and lung function of patients.
4. Pneumination through bronchial sections
Some of the more seriously ill patients, with a full pulmonary irradiation treatment, cannot effectively improve clinical symptoms and require repeated pulmonary irrigation.
Lung transplant
Applicable: If the treatment is ineffective and the patient is seriously ill, a lung transplant may be considered.
Risks: Pulmonary transplants treat pneumoconiosis with high risk, high trauma and long-term immunosuppressants to prevent exclusion.
6. Other assistive treatments
Oxygen: For patients with low oxygen haemorrhagic conditions, the treatment can be supported by oxygen.
Vaccination: Influenza and pneumonia vaccines, as pneumoblicodism can cause functional impairment of pneumocococeroses and lead to influenza and pneumonia.
In general, pneumoblicoplasia treatment requires a combination of clinical symptoms of patients, examination results, video-testing, pneumatic slurry testing, pulmonary tissue pathology examinations and genetic tests. Treatment includes, inter alia, full pulmonary irradiation, medication, lung transplants, etc., and requires the active cooperation of patients with healthy lifestyles and complementary treatments.
